Analysis of Irbesartan and Amlodipine Besilateusing HPLC

Importance of the Topic

The prevalence of hypertension and diabetic nephropathy necessitates precise monitoring of antihypertensive agents. Simultaneous quantification of irbesartan and amlodipine besilate addresses the need for efficient quality control in pharmaceutical production.

Objectives and Study Overview

This study aimed to develop and validate a robust reversed-phase HPLC method for the simultaneous analysis of irbesartan and amlodipine besilate. The focus was on achieving baseline separation, reproducibility, and suitability for routine quality assurance.

Methodology and Instrumentation

The analysis was performed on a Nexera-i MT system using a Shim-pack VP-ODS column (150 mm × 4.6 mm I.D., 5 μm). The mobile phase comprised methanol and 0.02 mmol/L sodium phosphate buffer (pH 3.0) in a 3:2 ratio. Chromatographic conditions included a flow rate of 1.0 mL/min, column temperature of 40 °C, injection volume of 10 μL, and UV detection at 237 nm (semimicro cell).

Key Results and Discussion

The method achieved clear baseline separation of both analytes with sharp peak shapes and retention times suitable for high-throughput analysis. System suitability tests indicated consistent plate counts and symmetry factors, confirming method precision.

Benefits and Practical Applications

• Rapid and reliable assay for combined dosage forms
• High reproducibility ideal for regulatory compliance
• Simple mobile phase composition facilitating routine use

Future Trends and Potential Applications

Advances may include integration with mass spectrometric detection for enhanced sensitivity, adoption of ultrahigh-performance LC to reduce analysis time, and exploration of green solvents to minimize environmental impact.

Conclusion

The developed HPLC method provides a dependable tool for simultaneous determination of irbesartan and amlodipine besilate in pharmaceutical formulations. Its robustness and simplicity support widespread application in QA/QC laboratories.

References

• Application News L523 (JP, ENG), Shimadzu Corporation, Dec. 2021, ERAS-1000-0121